Artivion, Inc. (NYSE:AORT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Artivion, Inc. (NYSE:AORT) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $44.1667.

Several analysts have commented on the stock. Citizens Jmp decreased their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Weiss Ratings cut shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, June 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Friday, April 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Finally, Citigroup reissued a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st.

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the sale, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after buying an additional 399 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the period. Finally, KBC Group NV bought a new stake in shares of Artivion in the fourth quarter valued at approximately $65,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Price Performance

AORT opened at $26.54 on Friday. The stock has a fifty day moving average price of $23.42 and a 200 day moving average price of $31.16. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of 110.60 and a beta of 1.25.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a return on equity of 7.15% and a net margin of 2.55%. Analysts forecast that Artivion will post 0.5 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.